Pacira pain product fails Phase III trial
This article was originally published in Scrip
Executive Summary
Pacira Pharmaceuticals' surgical pain product Exparel (bupivacaine liposome injectable suspension) has failed a Phase III trial as an intercostal nerve block for posterolateral thoracotomy.